Bharat Biotech marks 30 years with new anniversary logo at Hyderabad’s Genome Valley
Founded in 1996, Bharat Biotech was the anchor tenant of what is now Genome Valley, Asia’s largest life sciences cluster
By Newsmeter Network
Mrs. Suchitra Ella, MD, and Dr. Krishna Ella, Executive Chairman, launching the 30-year logo and celebration.
Hyderabad: Bharat Biotech celebrates 30 years of operation by unveiling a commemorative anniversary logo at its Genome Valley headquarters in Hyderabad, marking its evolution from a regional pioneer into a global life-sciences leader.
The founders—Dr Krishna Ella, the executive chairman and Suchitra Ella, the managing director—revealed the new branding before thousands of employees, signalling a year-long celebration of three decades of ‘science for society’, the company said in a statement.
A legacy of ‘firsts’
Founded in 1996, Bharat Biotech was the anchor tenant of what is now Genome Valley, Asia’s largest life sciences cluster. What began as a mission to create an affordable Hepatitis B vaccine has grown into a massive enterprise with a portfolio of 20 vaccines and over 220 granted patents.
The company’s trajectory is defined by high-stakes innovation, including:
ROTAVAC®: A breakthrough Rotavirus vaccine provided to public health programs for just $1 per dose.
Typbar TCV®: The world’s first clinically proven Typhoid Conjugate Vaccine.
COVAXIN®: India’s first indigenous COVID-19 vaccine, developed in record time during the global pandemic.
Global Rabies Leadership: Through its subsidiary Chiron Behring, the company is now the world’s largest manufacturer of rabies vaccines. “Thirty years ago, we started with a simple belief: that Indian science can solve global health challenges,” said Dr Krishna Ella. “Our strength has always been our scientists and our commitment to innovation with purpose.”
Three decades of impact
The scale of Bharat Biotech’s contribution to global immunisation is reflected in its staggering reach:
Does delivered: Over 9 billion
Global Reach: 125 plus countries
Patents Granted: 220 plus
Workforce: 4000 plus employees
Scientific portfolio: 20 vaccines and 4 biotherapeutics
Gene therapy and beyond
While the anniversary honours the past, the leadership team is firmly focused on the future.
The company is currently expanding into cell and gene therapy through its newest arm, Nucelion Therapeutics, and scaling production at Sapigen Biologix in Odisha, a facility capable of producing 8 billion doses annually.
“As we enter advanced cell and gene therapy, we remain guided by the same mission,” stated Suchitra Ella. “We built our own intellectual property because we believed India must lead, not follow.”
With ongoing trials for MTBVAC (a tuberculosis vaccine candidate) and expanding research into Chikungunya and Zika, Bharat Biotech enters its 31st year not just as a manufacturer, but as a primary architect of the world’s future biosecurity.
